To the editor:

The antiplatelet agent ticlopidine is associated with the rapid onset of a thrombotic microangiopathy (TMA) resembling thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (aHUS). These disorders occur in 0.06% of individuals exposed to ticlopidine, usually within 1.5 to 6 weeks of exposure.1,2  The vast majority of ticlopidine TMAs are accompanied by antibody-mediated inhibition of the protease ADAMTS13, making them similar to idiopathic TTP.3,4  However, ADAMTS13 deficiency alone is not sufficient for the development of TMAs. Our group has shown that exposure to both the pharmacologic levels of ticlopidine and plasma from patients with ticlopidine TMAs induces apoptosis in primary human microvascular endothelial cells, suggesting that ticlopidine-induced endothelial cell apoptosis is a provoking factor in ticlopidine TMAs.5  In other TMAs such as aHUS, complement regulatory protein mutations represent another provoking factor for the development of these diseases.6  Complement mutations have not been studied in ticlopidine TMAs.

We obtained plasma samples from 4 consecutive patients with TMAs that occurred within 2.5 to 4 weeks of ticlopidine exposure (Table 1).7  ADAMTS13 activity and inhibitor titers were determined, as previously described by Bennett et al.8  All patients had thrombocytopenia, schistocytosis, markedly elevated levels of lactate dehydrogenase (LDH), renal impairment, and significantly decreased ADAMTS13 activity. Three of 4 had ADAMTS13 inhibitors. Plasma levels of C5a and C5b-9 (membrane attack complex) were measured by enzyme-linked immunosorbent assay (Quidel). Genomic DNA was isolated from plasma using the QIAamp kit (Qiagen). To determine the presence of complement mutations, we selected primers to soluble complement factor H (CFH), complement factor I, and membrane-linked membrane cofactor protein, 3 complement regulatory factors with mutations that have been identified with high frequency in aHUS.4,5  We found substantially elevated levels of membrane attack complex despite normal C5a levels, and all 4 patients had CFH genetic abnormalities (Table 2). Two of the 3 polymorphisms are of known functional significance, and even heterozygous CFH mutations are sufficient to develop aHUS.7,9 

Table 1

Clinical characteristics of 4 patients with ticlopidine TMAs

Patient codeAgeSexDuration of ticlopidine (wk)Creatinine (μmol/L)Platelets pretherapyPlatelets posttherapyLDH pretherapy (U/L)LDH posttherapy (U/L)OutcomePEX sessions (N)ADAMTS13 Activity (%)*
010 84 110 40 235 2555 NA Death <5 
022 77 150 131 1084 214 Survival 10 <5 
003 78 3.5 260 33 93 1005 1736 Death <5 
012 42 2.5 110 13 323 790 170 Survival 30 <5 
Patient codeAgeSexDuration of ticlopidine (wk)Creatinine (μmol/L)Platelets pretherapyPlatelets posttherapyLDH pretherapy (U/L)LDH posttherapy (U/L)OutcomePEX sessions (N)ADAMTS13 Activity (%)*
010 84 110 40 235 2555 NA Death <5 
022 77 150 131 1084 214 Survival 10 <5 
003 78 3.5 260 33 93 1005 1736 Death <5 
012 42 2.5 110 13 323 790 170 Survival 30 <5 

Platelet values expressed as ×103.

F, female; M, male; NA, not available; PEX, plasma exchange.

*

ADAMTS13 was assessed by both FRET-VWF assay (<5%) and immunoblot activity (<10%).

Table 2

Complement levels of 4 patients with ticlopidine TMAs and corresponding mutations

Patient codeC5a (ng/mL) (normal range, 0.3-70)sC5b-9 (ng/mL) (normal range, 100-300)CFH polymorphism
010 32.08 4862 Homozygous exon 18 E936D 
022 51.21 6023 Heterozygous exon 18 Q950H 
003 27.74 5904 Heterozygous exon 18 E936D 
012 50.96 6229 Heterozygous exon 19 N1050Y 
Patient codeC5a (ng/mL) (normal range, 0.3-70)sC5b-9 (ng/mL) (normal range, 100-300)CFH polymorphism
010 32.08 4862 Homozygous exon 18 E936D 
022 51.21 6023 Heterozygous exon 18 Q950H 
003 27.74 5904 Heterozygous exon 18 E936D 
012 50.96 6229 Heterozygous exon 19 N1050Y 

Primers used are exon 18 first step TAGACAGACAGACACCAGAAGG (forward), GGTACCACTTACACTTTGAATGAAGA (reverse); exon 18 second step AATTTATGAGTTAGTGAAACCTGAAT (forward), GGTACCACTTACACTTTGAATGAAGA (reverse); exon 19 first step TGTGTAATCTCAATTGCTACGGCT (forward), GGCTGGGCCCACACATTA (reverse); and exon 19 second step ACAAAATGGCTAATATATTTTCTCAAG (forward), GGCTGGGCCCACACATTA (reverse).

CFH, complement factor H.

This is the first report of CFH mutations in ticlopidine TMAs. These mutations are otherwise uncommon in healthy individuals and have a background mutation rate of <5% in northern Europeans.10,11  ADAMTS13 deficiency has previously been considered to be pathognomonic of TTP. However, complement regulatory factor mutations represent another independent susceptibility factor in many types of TMAs, and their presence in addition to ADAMTS13 deficiency may be required for the onset of disease. If a complement mutation is required for TMA development after ticlopidine exposure, it could explain the rarity of ticlopidine TMAs despite the fact that the drug causes microvascular endothelial cell injury in vitro.5  Unlike idiopathic TTP, both aHUS and ticlopidine TMAs respond poorly to plasma exchange, even though hematologic parameters may normalize. Renal disease and overall mortality are not affected, and LDH levels do not return to normal, which suggests ongoing endothelial injury.9  We hypothesize that ticlopidine TMAs occur as a result of a failure to regulate complement on endothelial cell surfaces after cell injury, leading to ongoing microvascular damage. This defect may be present in other TMAs. We recently illustrated the role of complement in a patient with severe refractory idiopathic TTP with ADAMTS13 <5% and a high inhibitor titer. He rapidly responded to anti-C5 therapy after other treatment failures.12  No complement mutations were detected utilizing a commercially available platform. Subsequent analysis, however, did reveal a CFH mutation (unpublished data).12  In conclusion, complement regulatory protein mutations may form the basis for TMA susceptibility and should be further studied.

Contribution: J.C. performed DNA extraction and collected clinical information; H.-M.T. performed ADAMTS13 testing; S.E. and R.S. performed semi-nested PCR on all DNA samples; J.L. and J.C. analyzed the data and authored the manuscript; and all authors contributed equally to the editing and revision of this work.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

H.-M.T. is not currently affiliated with any institution.

Correspondence: John Chapin, Division of Hematology-Oncology Payson 3, Weill Cornell Medical College, 525 E 68th St, New York, NY 10065; e-mail: [email protected].

1
Bennett
CL
Davidson
CJ
Raisch
DW
Weinberg
PD
Bennett
RH
Feldman
MD
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.
Arch Intern Med
1999
159
21
2524
2528
2
Bennett
CL
Weinberg
PD
Rozenberg-Ben-Dror
K
Yarnold
PR
Kwaan
HC
Green
D
Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.
Ann Intern Med
1998
128
7
541
544
3
Tsai
HM
Rice
L
Sarode
R
Chow
TW
Moake
JL
Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.
Ann Intern Med
2000
132
10
794
799
4
Sadler
JE
A new name in thrombosis, ADAMTS13.
Proc Natl Acad Sci USA
2002
99
18
11552
11554
5
Mauro
M
Zlatopolskiy
A
Raife
TJ
Laurence
J
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.
Br J Haematol
2004
124
2
200
210
6
Noris
M
Remuzzi
G
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.
Clin Exp Immunol
2008
151
2
199
209
7
Caprioli
J
Castelletti
F
Bucchioni
S
et al
International Registry of Recurrent and Familial HUS/TTP
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.
Hum Mol Genet
2003
12
24
3385
3395
8
Bennett
CL
Kim
B
Zakarija
A
et al
SERF-TTP Research Group
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
J Am Coll Cardiol
2007
50
12
1138
1143
9
Laurence
J
Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv in Hematol Oncol. 2012;10(10)(suppl 17): 1-11
10
Neumann
HP
Salzmann
M
Bohnert-Iwan
B
et al
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.
J Med Genet
2003
40
9
676
681
11
Jönson
A
Nilsson
SC
Ahlqvist
E
et al
Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus.
Arthritis Res Ther
2011
13
R206
1
9
12
Chapin
J
Weksler
B
Magro
C
Laurence
J
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura.
Br J Haematol
2012
157
6
772
774
Sign in via your Institution